At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease
In Brief
A clinical study evaluating Supervised Treadmill Exercise Therapy, Telmisartan, and 2 other interventions for Peripheral Artery Disease. Completed, enrolled 114 participants across 3 sites.
Detailed Summary
The TELEX trial will establish whether telmisartan alone improves walking performance in people with peripheral artery disease (PAD). The TELEX trial will also determine whether telmisartan plus supervised exercise improves walking performance more than either therapy alone. TELEX is a randomized controlled clinical trial (2 x 2 factorial design) of 112 participants with PAD randomized to one of four arms: Group A: telmisartan + supervised exercise therapy; Group B: telmisartan + a "no exercise" control group; Group C: placebo + supervised exercise therapy; and Group D: placebo + a "no exercise" control group.
Study Details
Timeline
Interventions
Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.